InflaRx将于11月10日公布在患有脓性皮炎和慢性自发性荨麻疹的参与者中进行的口服C5 ar抑制剂INF904的2a期临床研究的数据

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it expects to report topline data from the Phase 2a clinical trial of oral C5aR inhibitor INF904 in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) in a pre-market press release on Monday, November 10, 2025.